You may recall Michael's caution re: D&Q therapy @ thread https://www.longecit...red-supplement/ :
Additionally, the results of a senescent cell ablation study by Dmitry Bulavin at Undoing Aging (I hope video will be up soon) scared the snot out of me; I am awaiting to read the paper and understand more before adopting any senolytic protocol (though fisetin, specifically, seems to be less hepatotoxic than other senolytics, and liver damage was the site of the horror in the Bulavin study).
Dr. Balavin's presentation @ Undoing Aging 2019 is now available online:
Massive senolysis of LSEC's with replacement with collagen ( ie, fibrosis ) on a massive scale, and commensurate morbidity need to be reconciled with other D&Q protocols consistent with improvement in healthspan.
Following the talk, Dr. Balavin suggested that apparent absence of these horrible consequences in the other D&Q protocols may not be differences in protocols, but that such concerning liver injury may have been overlooked.
Yet those other D&Q models have suggested overall less morbidity rather than vice-versa.
And on the flipside, liver pathology was reviewed here, https://www.nature.c...les/ncomms15691 "The grade of steatosis (0–3), disease activity, including semi-quantification of lobular inflammation and hepatocyte ballooning, and stage of fibrosis (0–4) were assessed [....and...] calculated for each biopsy," - somewhat but not entirely reassuring given the different model.
Most concerning was that the pathology with periodic lifelong, early-onset senolysis was reproduced in his second model, utilizing a mid-life, hit-and-run senolytic approach.
Looking forward to reviewing his forthcoming publication.
Edited by researchgrounded, 23 May 2020 - 12:50 AM.